Business Context and Reporting Period
This Form 8-K was filed by Transdel Pharmaceuticals, Inc. on February 23, 2012. The report details corporate governance changes, specifically a reverse stock split and a name change to Imprimis Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes rather than financial performance.
Material Changes
- Reverse Stock Split: A 1-for-8 reverse split of common stock became effective on February 24, 2012.
- Name Change: The company's name was changed to Imprimis Pharmaceuticals, Inc., with the amendment to the Articles of Incorporation effective February 29, 2012.
- Stock Symbol: The new temporary symbol is TDLPD. The "D" suffix will be removed after 20 business days, resulting in the permanent symbol IMMY.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. The document serves solely to notify the market of the effective dates for the stock split and name change as approved by FINRA and the Delaware Secretary of State.
Investor Verification Checklist
- Confirm the effective date of the 1-for-8 reverse stock split (February 24, 2012).
- Verify the transition of the stock symbol from the temporary TDLPD to the permanent IMMY.
- Check the official filing of the name change to Imprimis Pharmaceuticals, Inc. with the Delaware Secretary of State (effective February 29, 2012).